X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
EGRIFTA F8® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Lead Product(s): Egrifta
Therapeutic Area: Infections and Infectious Diseases Product Name: Egrifta MDV
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
EGRIFTA F8® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Lead Product(s): Egrifta
Therapeutic Area: Dermatology Product Name: Egrifta F8
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
EGRIFTA SV® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Lead Product(s): Egrifta
Therapeutic Area: Dermatology Product Name: Egrifta SV
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: World Orphan Drug Alliance
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2023
Details:
The priorities include the advancement of the clinical oncology pipeline, which is currently in a larger Phase 1b basket study, and the rapid growth of our existing marketed brands, EGRIFTA SV® and Trogarzo®.
Lead Product(s): Egrifta
Therapeutic Area: Dermatology Product Name: Egrifta SV
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Marathon Asset Management
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing July 13, 2022
Details:
The Phase 3 clinical trial will be a multicenter, double-blind, placebo-controlled two-part study to evaluate the safety and efficacy of tesamorelin in liver-biopsy confirmed patients with NAS score of at least 4 and stage 2 or 3 fibrosis.
Lead Product(s): Egrifta
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Egrifta
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2021
Details:
Oral presentation includes data on the mechanism of effect of tesamorelin in nonalcoholic fatty liver disease (NAFLD) will be given by Lindsay T Fourman at The Liver Meeting® 2020 of the American Association for the Study of Liver Diseases (AASLD).
Lead Product(s): Egrifta
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Tesamorelin F8
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2020
Details:
The company is also plan on filing patent applications in other jurisdictions to expand our protection of tesamorelin.
Lead Product(s): Egrifta
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: F8
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
This new formulation, known as “F8”, is stable at room temperature for up to seven days after reconstitution and its volume of administration is only 0.16 mL making it possible to have a single multidose vial containing seven days of treatment.
Lead Product(s): Egrifta
Therapeutic Area: Infections and Infectious Diseases Product Name: F8
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
Theratechnologies Inc. signed of long-term agreements with the MGH towards the development of tesamorelin for the treatment of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.
Lead Product(s): Egrifta
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Theratechnologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
